Both in Pharmaceuticals
Longeveron vs Skye Bioscience
Over the past year LGVN returned −80.3% and SKYE returned −89.6%; their daily moves had a correlation of 0.03.
LGVN −80.3% SKYE −89.6%Growth of $1, one year, split-adjusted
| Metric | LGVN | SKYE |
|---|---|---|
| Price | $1.75 | $1.31 |
| Market cap | $5.6M | $5.8M |
| Today | −1.69% | −13.82% |
| 1 month | −34.9% | −18.6% |
| 6 months | −79.4% | −81.4% |
| Year to date | −65.4% | −78.2% |
| 1 year | −81.2% | −89.5% |
| Revenue growth (YoY) | −9.2% | — |
| Gross margin | 63.4% | — |
| Net margin | −2116.0% | — |
| P/E (TTM) | — | — |
| Price / sales | 4.7× | — |
| Net cash | $10.1M | $9.9M |
| Dividend yield | — | — |
| Volatility (60d) | 708.8% | 617.6% |
| Short % of float | 2.8% | 0.6% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).